S&P Futures
4,132.50+4.75(+0.12%)Dow Futures
33,743.00+34.00(+0.10%)Nasdaq Futures
13,766.75+16.50(+0.12%)
9 Meters Biopharma, Inc. (NMTR)
1.1700 +0.01 (0.86%)
After hours: 7:56PM EDT
Chart Events
Performance Outlook
| Previous Close | 1.0800 |
| Open | 1.1100 |
| Bid | 1.1400 x 3200 |
| Ask | 1.1800 x 28000 |
| Day's Range | 1.0989 - 1.2100 |
| 52 Week Range | 0.4300 - 2.2600 |
| Volume | 5,065,743 |
| Avg. Volume | 11,168,331 |
| Market Cap | 290.661M |
| Beta (5Y Monthly) | -0.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 12, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.60 |
- ACCESSWIRE
9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit
RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will participate in the 7th Annual Truist Securities Life Sciences Summit and invites investors to participate in one-on-one meetings.
- ACCESSWIRE
9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will enter into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).
- ACCESSWIRE
9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study
RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will collaborate with the Celiac Disease Foundation (CDF) to support clinical trial enrollment in 9 Meters' Phase 3 study, CeDLara, for their drug candidate larazotide in celiac disease.
